GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shinpoong Pharmaceutical Co 019170.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

7,980

+0.63%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩234.68bn

FY2016FY2025

Net income

₩8.83bn

FY2016FY2025

Free cash flow

₩13.26bn

FY2016FY2025

Shareholders' equity

₩269.98bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩234.68bn₩221.09bn₩200.23bn₩209.29bn₩189.24bn₩197.75bn₩189.72bn₩187.39bn₩185.00bn₩194.15bn
Gross profit₩102.67bn₩81.80bn₩80.28bn₩77.97bn₩77.39bn₩76.53bn₩76.18bn₩75.89bn₩80.12bn₩87.93bn
Research and development₩10.44bn₩17.88bn₩42.28bn₩30.38bn₩17.33bn₩5.62bn₩5.97bn₩4.87bn₩4.63bn₩6.39bn
Operating income₩10.37bn−₩17.03bn—₩77.97bn−₩14.31bn₩9.35bn₩9.73bn₩7.75bn₩7.81bn₩9.57bn
Net income₩8.83bn−₩15.39bn−₩57.33bn−₩35.38bn−₩11.58bn₩5.00bn₩5.32bn₩2.80bn₩904.9m−₩18.59bn
Diluted earnings per share176.60-307.91-1,147.13-707.93-231.80100.11106.5356.1118.11-372.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩352.47bn₩342.09bn₩350.08bn₩361.54bn₩392.58bn₩487.15bn₩380.11bn₩380.95bn₩385.61bn₩416.49bn
Total liabilities₩81.74bn₩84.00bn₩79.30bn₩30.78bn₩38.03bn₩112.82bn₩170.99bn₩173.47bn₩175.50bn₩199.64bn
Debt₩11.37bn₩4.60bn————₩106.06bn₩107.44bn₩112.57bn₩121.44bn
Shareholders' equity₩269.98bn₩256.82bn₩269.59bn₩329.61bn₩353.49bn₩373.37bn₩208.18bn₩206.47bn₩209.81bn₩216.55bn
Shares outstanding50m50m50m50m50m50m50m50m50m50m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩17.25bn−₩15.15bn−₩24.81bn−₩26.44bn−₩71.03bn₩20.06bn₩19.35bn₩32.05bn₩10.15bn₩18.96bn
Capital spending−₩3.99bn−₩6.09bn−₩15.03bn−₩6.23bn−₩4.42bn−₩2.65bn−₩12.07bn−₩1.79bn−₩3.08bn−₩1.50bn
Free cash flow₩13.26bn−₩21.24bn−₩39.84bn−₩32.67bn−₩75.45bn₩17.41bn₩7.28bn₩30.26bn₩7.07bn₩17.46bn
Dividends paid————−₩5.16bn−₩5.16bn−₩5.16bn−₩5.16bn——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩63.89bn₩54.53bn₩58.04bn₩62.61bn₩58.62bn₩55.41bn₩55.26bn₩55.80bn
Gross profit₩26.99bn₩21.41bn₩25.00bn₩28.70bn₩27.29bn₩21.68bn₩19.38bn₩22.22bn
Operating income−₩8.03bn₩1.06bn₩3.87bn₩7.69bn₩4.94bn−₩1.76bn−₩12.12bn₩492.7m
Net income−₩8.01bn₩358.5m₩461.4m₩6.38bn₩3.27bn−₩1.28bn−₩12.64bn−₩98.4m
Diluted earnings per share-160.367.179.23127.6465.43-25.70-252.91-1.97
Cash from operations−₩1.15bn₩6.36bn₩3.42bn₩8.94bn₩4.72bn₩177.0m−₩16.01bn₩6.49bn
Capital spending−₩1.80bn−₩557.0m−₩694.0m−₩1.43bn−₩873.0m−₩994.0m−₩1.85bn−₩1.50bn
Free cash flow−₩2.94bn₩5.80bn₩2.72bn₩7.51bn₩3.85bn−₩817.0m−₩17.86bn₩5.00bn
Total assets₩366.50bn₩371.88bn₩352.47bn₩341.59bn₩337.61bn₩336.92bn₩342.09bn₩337.48bn
Debt₩10.80bn₩11.08bn₩11.37bn₩2.79bn₩3.62bn₩4.60bn₩4.60bn—
Shareholders' equity₩277.18bn₩291.46bn₩269.98bn₩263.42bn₩256.60bn₩255.36bn₩256.82bn₩266.90bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.9%3.5%1.8%
Operating income-49.0%2.1%9.4%
Net income—12.0%19.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin40.5%39.6%39.7%41.0%
Operating margin-1.5%———
Net margin-1.4%-11.5%-8.5%-5.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings79.5-33.5-11.8-29.9-137.8—68.0114.3424.7-16.0
Price to sales3.02.33.45.08.431.31.91.72.11.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Dec 2020.

FY2021FY2015FY2014FY2013FY2012FY2011FY2010FY2009
Paid in the year100.0048.07736.98253.3451.28849.79349.79441.495
  • 1.04-for-1 split · 29 Dec 2014
  • 1.04-for-1 split · 27 Dec 2013
  • 1.04-for-1 split · 27 Dec 2012
  • 1.04-for-1 split · 28 Dec 2011
  • 10-for-1 split · 4 May 2011
  • 1.03-for-1 split · 29 Dec 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.